These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer. Lim SM, Chang H, Cha YJ, Liang S, Tai YC, Li G, Pestova E, Policht F, Perez T, Soo RA, Park WY, Kim HR, Shim HS, Cho BC. Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404 [Abstract] [Full Text] [Related]
5. An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology. Piton N, Lanic MD, Marguet F, Lamy A, Blanchard F, Guisier F, Viennot M, Salaün M, Thiberville L, Jardin F, Sabourin JC, Ruminy P. Lab Invest; 2021 May; 101(5):648-660. PubMed ID: 33495574 [Abstract] [Full Text] [Related]
6. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma. Jang JS, Wang X, Vedell PT, Wen J, Zhang J, Ellison DW, Evans JM, Johnson SH, Yang P, Sukov WR, Oliveira AM, Vasmatzis G, Sun Z, Jen J, Yi ES. J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444 [Abstract] [Full Text] [Related]
10. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Zhao W, Choi YL, Song JY, Zhu Y, Xu Q, Zhang F, Jiang L, Cheng J, Zheng G, Mao M. Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202 [Abstract] [Full Text] [Related]
11. Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A. Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897 [Abstract] [Full Text] [Related]
12. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, Li B, Cai D, Shen L, Sun Y, Chen H. Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636 [Abstract] [Full Text] [Related]
13. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M. Clin Cancer Res; 2012 Dec 15; 18(24):6599-608. PubMed ID: 23052255 [Abstract] [Full Text] [Related]
14. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC. Melchior L, Hirschmann A, Hofman P, Bontoux C, Concha A, Mrabet-Dahbi S, Vannuffel P, Watkin E, Putzová M, Scarpino S, Cayre A, Martin P, Stoehr R, Hartmann A. Virchows Arch; 2024 Apr 15; 484(4):677-686. PubMed ID: 38492039 [Abstract] [Full Text] [Related]
17. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Lee SE, Lee B, Hong M, Song JY, Jung K, Lira ME, Mao M, Han J, Kim J, Choi YL. Mod Pathol; 2015 Apr 15; 28(4):468-79. PubMed ID: 25234288 [Abstract] [Full Text] [Related]